お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
906567

アジア太平洋地域の薬剤開発市場規模、シェア、動向分析:手法別(社内、アウトソース)、プロセスステップ別(DMPK、安全性評価)、治療領域別、セグメント予測(2019~2026年)

Asia Pacific Drug Development Market Size, Share & Trends Analysis Report By Mode (In house, Outsourced), By Process Step (DMPK, Safety Assessment), By Therapeutic Area, And Segment Forecasts, 2019 - 2026

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 240 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.13円
アジア太平洋地域の薬剤開発市場規模、シェア、動向分析:手法別(社内、アウトソース)、プロセスステップ別(DMPK、安全性評価)、治療領域別、セグメント予測(2019~2026年)
出版日: 2019年07月09日
発行: Grand View Research, Inc.
ページ情報: 英文 240 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アジア太平洋地域の薬剤開発市場規模は今後CAGR6.54%で拡大し、2026年までに624億6,000万米ドルに達すると予測されています。大手製薬会社が研究費の増加と減収などの課題に直面しており、アジアの薬剤開発部門の大きな拡大へとつながっています。

当レポートでは、アジア太平洋地域の薬剤開発市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 エグゼクティブサマリー

第2章 調査方法

第3章 市場変動、動向、範囲

  • 市場セグメンテーションと範囲
    • 市場促進因子分析
    • 市場阻害因子分析
  • 浸透および成長見通しマッピング
  • SWOT分析
  • 業界分析:ポーターズ分析

第4章 手法別予測と動向分析

  • 動向分析
  • 社内
  • アウトソース

第5章 プロセスステップ別予測と動向分析

  • 動向分析
  • プロセス研究開発
  • 調製
  • 分析・安全性試験
  • 薬剤代謝・薬物動態
  • 安全性評価(毒性学)
  • 規制対応
  • 包装

第6章 治療分野別予測と動向分析

  • 動向分析
  • 腫瘍
  • 炎症・免疫
  • 心臓
  • 神経科学
  • その他

第7章 国別予測と動向分析

  • 国別市場シェア
  • インド
  • 中国
  • シンガポール
  • 日本
  • 韓国
  • インドネシア
  • オーストラリア
  • マレーシア
  • ベトナム

第8章 競合環境

  • 戦略的枠組み
  • 市場参入分類
  • 企業プロファイル
図表

List of Tables

  • TABLE 1 ASEAN guidelines on stability study and shelf-life of traditional medicines
  • TABLE 2 Regulatory bodies governing drug development in Asia Pacific
  • TABLE 3 India drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 4 India drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 5 India drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 6 China drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 7 China drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 8 China drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 9 Singapore drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 10 Singapore drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 11 Singapore drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 12 Japan drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 13 Japan drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 14 Japan drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 15 South Korea drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 16 South Korea drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 17 South Korea drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 18 Indonesia drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 19 Indonesia drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 20 Indonesia drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 21 Australia drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 22 Australia drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 23 Australia drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 24 Malaysia drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 25 Malaysia drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 26 Malaysia drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 27 Vietnam drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 28 Vietnam drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 29 Vietnam drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)

List of Figures

  • FIG. 1 Market snapshot
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 Penetration & growth prospect mapping for Process Step Scope, 2018
  • FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14 Porter's Five Forces Analysis
  • FIG. 15 Asia Pacific drug development market: Mode outlook key takeaways
  • FIG. 16 Asia Pacific drug development market: Mode movement analysis
  • FIG. 17 Asia pacific in house drug development market, 2015 - 2026 (USD Million)
  • FIG. 18 Asia pacific outsourced drug development market, 2015 - 2026 (USD Million)
  • FIG. 19 Asia Pacific drug development market: Process step outlook key takeaways
  • FIG. 20 Asia Pacific drug development market: Process step movement analysis
  • FIG. 21 Asia pacific drug development market for process research development, 2015 - 2026 (USD Million)
  • FIG. 22 Asia pacific drug development market for formulation step, 2015 - 2026 (USD Million)
  • FIG. 23 Asia pacific drug development market for analytical & stability studies, 2015 - 2026 (USD Million)
  • FIG. 24 Asia pacific drug development market for Drug Metabolism and Pharmacokinetics (DMPK), 2015 - 2026 (USD Million)
  • FIG. 25 Toxicology studies during drug development
  • FIG. 26 Asia pacific drug development market for safety assessment (Toxicology), 2015 - 2026 (USD Million)
  • FIG. 27 Asia pacific drug development market for regulatory compliance, 2015 - 2026 (USD Million)
  • FIG. 28 Asia Pacific drug development market for packaging, 2015 - 2026 (USD Million)
  • FIG. 29 Asia Pacific drug development market: Therapeutic area outlook key takeaways
  • FIG. 30 Asia Pacific drug development market: Therapeutic area movement analysis
  • FIG. 31 Asia Pacific drug development market for oncology, 2015 - 2026 (USD Million)
  • FIG. 32 Asia Pacific drug development market for inflammation & immunology, 2015 - 2026 (USD Million)
  • FIG. 33 Asia Pacific drug development market for cardiology, 2015 - 2026 (USD Million)
  • FIG. 34 Asia Pacific drug development market for neuroscience, 2015 - 2026 (USD Million)
  • FIG. 35 Asia Pacific drug development market for other therapeutic area, 2015 - 2026 (USD Million)
  • FIG. 36 Regional market place: Key takeaway
  • FIG. 37 Asia Pacific drug development market: Country outlook, 2018 & 2026
  • FIG. 38 India drug development market, 2015 - 2026 (USD Million)
  • FIG. 39 India drug development market, 2015 - 2026 (USD Million)
  • FIG. 40 Singapore drug development market, 2015 - 2026 (USD Million)
  • FIG. 41 Japan drug development market, 2015 - 2026 (USD Million)
  • FIG. 42 South Korea drug development market, 2015 - 2026 (USD Million)
  • FIG. 43 Indonesia drug development market, 2015 - 2026 (USD Million)
  • FIG. 44 Australia drug development market, 2015 - 2026 (USD Million)
  • FIG. 45 Malaysia drug development market, 2015 - 2026 (USD Million)
  • FIG. 46 Vietnam drug development market, 2015 - 2026 (USD Million)
  • FIG. 47 Strategy framework
  • FIG. 48 Market participant categorization
目次
Product Code: GVR-3-68038-222-8

The Asia Pacific drug development market is expected to reach USD 62.46 billion by 2026 and is projected to expand at a CAGR of 6.54%, according to a new report by Grand View Research, Inc. Challenges pertaining to the escalating research costs and shrinking revenue faced by major pharma companies have led to the significant expansion of Asian drug development sector. A rapidly expanding healthcare infrastructure, low operating costs, and a growing patient population have contributed to the recognition of Asian countries as an ideal site for low-cost drug development.

Furthermore, the growing acceptance of clinical trial data generated in Asia by Western drug regulators, including the EMA and U.S. FDA, is one of the key market drivers. This is primarily because of the increasing similarities of Asian disease demographics to that of the Western nations.

Various government policies have been formulated to promote implementation of digital and advanced analytics, such as artificial intelligence, in the region. Moreover, the pharma companies are collaborating with AI-based companies to leverage algorithms and cloud computing to transform their drug development process.

The contract research organizations are experiencing increasing levels of interest in Asian countries from their U.S. -based client base. This is a testament to the lucrative growth of Asia Pacific market, driving its growth in the coming years.

Further key findings from the report suggest:

  • Outsourced mode of pharmaceutical development led the market and is expected to maintain its dominance throughout the forecast period, due to the fact that the companies are investing or redirecting their significant investments from already existing R&D centers in Europe and U.S. to emerging centers in Asia
  • Analytical & stability studies captured the largest revenue share in the market, due to the high usage of advanced and relative expensive technologies such as Electron Paramagnetic Resonance (EPR) spectroscopy
  • Oncology is estimated to be the highest revenue generating segment, due to the presence of a substantial number of cancer targeting therapeutics in clinical development phase. This segment is expected to maintain a fast CAGR during the forecast period owing to wide acceptance of personalized therapy in cancer treatment
  • Strong government support for innovation and large and diverse domestic pharma industry of China has led to the dominance of China over other countries in the Asia Pacific drug development market
  • Furthermore, the launch of several start-ups in India is expected to serve as a significant source of revenue to the Indian pharmaceutical industry
  • Some key contract service providers operating in the Asia Pacific drug development market are Eurofins Advinus; Covance Inc.; Celerion; and Parexel International Corporation. With the rising trend of outsourcing pharmaceutical manufacturing, these CROs are expected to witness great organic revenue growth
  • In house global pharmaceutical manufacturers such as Pfizer and AstraZeneca are also striving to gain competitive ground in the Asian market

Table of content

Chapter 1 Executive Summary

  • 1.1 Market Snapshot

Chapter 2 Research Methodology

  • 2.1 Information Procurement
  • 2.2 Information or Data Analysis
  • 2.3 Market Formulation & Validation

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Market Segmentation & Scope
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Rising pharma R&D outsourcing
      • 3.1.1.2 Growing accessibility to Artificial Intelligence (AI) for pharmaceutical research
      • 3.1.1.3 Expansion in the global drug developer in Asian market
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 Different approval timelines
      • 3.1.2.1 Presence of well-established players in western market
  • 3.2 Penetration & Growth Prospect Mapping For Process Step Scope, 2018
  • 3.3 Asia Pacific Drug Development Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 Asia Pacific Drug Development Market Categorization: Mode Estimates & Trend Analysis

  • 4.1 Asia Pacific Drug Development Market: Mode Movement Analysis
  • 4.2 In house
    • 4.2.1 Asia pacific in house drug development market, 2015 - 2026 (USD Million)
  • 4.3 Outsourced
    • 4.3.1 Asia pacific outsourced drug development market, 2015 - 2026 (USD Million)

Chapter 5 Asia Pacific Drug Development Market Categorization: Process Step Estimates & Trend Analysis

  • 5.1 Asia Pacific Drug Development Market: Process Step Movement Analysis
  • 5.2 Process Research Development
    • 5.2.1 Asia pacific drug development market for process research development, 2015 - 2026 (USD Million)
  • 5.3 Formulation
    • 5.3.1 Asia pacific drug development market for formulation step, 2015 - 2026 (USD Million)
  • 5.4 Analytical & stability studies
    • 5.4.1 Asia pacific drug development market for analytical & stability studies, 2015 - 2026 (USD Million)
  • 5.5 Drug Metabolism and Pharmacokinetics (DMPK)
    • 5.5.1 Asia pacific drug development market for Drug Metabolism and Pharmacokinetics (DMPK), 2015 - 2026 (USD Million)
  • 5.6 Safety Assessment (Toxicology)
    • 5.6.1 Asia pacific drug development market for safety assessment (Toxicology), 2015 - 2026 (USD Million)
  • 5.7 Regulatory Compliance
    • 5.7.1 Asia pacific drug development market for regulatory compliance, 2015 - 2026 (USD Million)
  • 5.8 Packaging
    • 5.8.1 Asia Pacific drug development market for packaging, 2015 - 2026 (USD Million)

Chapter 6 Asia Pacific Drug Development Market Categorization: Therapeutic Area Estimates & Trend Analysis

  • 6.1 Asia Pacific Drug Development Market: Therapeutic Area Movement Analysis
  • 6.2 Oncology
    • 6.2.1 Asia Pacific drug development market for oncology, 2015 - 2026 (USD Million)
  • 6.3 Inflammation & Immunology
    • 6.3.1 Asia Pacific drug development market for inflammation & immunology, 2015 - 2026 (USD Million)
  • 6.4 Cardiology
    • 6.4.1 Asia Pacific drug development market for cardiology, 2015 - 2026 (USD Million)
  • 6.5 Neuroscience
    • 6.5.1 Asia Pacific drug development market for neuroscience, 2015 - 2026 (USD Million)
  • 6.6 Others
    • 6.6.1 Asia Pacific drug development market for other therapeutic area, 2015 - 2026 (USD Million)

Chapter 7 Asia Pacific Drug Development Market Categorization: Country Estimates & Trend Analysis, by Mode, Process Step, & Therapeutic Area

  • 7.1 Asia Pacific Drug Development Market Share, By Country, 2018 & 2026
  • 7.2 India
    • 7.2.1 India drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.2.2 India drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.2.3 India drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.3 China
    • 7.3.1 China drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.3.2 China drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.3.3 China drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.4 Singapore
    • 7.4.1 Singapore drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.4.2 Singapore drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.4.3 Singapore drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.5 Japan
    • 7.5.1 Japan drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.5.2 Japan drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.5.3 Japan drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.6 South Korea
    • 7.6.1 South Korea drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.6.2 South Korea drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.6.3 South Korea drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.7 Indonesia
    • 7.7.1 Indonesia drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.7.2 Indonesia drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.7.3 Indonesia drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.8 Australia
    • 7.8.1 Australia drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.8.2 Australia drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.8.3 Australia drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.9 Malaysia
    • 7.9.1 Malaysia drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.9.2 Malaysia drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.9.3 Malaysia drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.10 Vietnam
    • 7.10.1 Vietnam drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.10.2 Vietnam drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.10.3 Vietnam drug development market, by therapuetic area, 2015 - 2026 (USD Million)

Chapter 8 Asia Pacific Drug Development Market: Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Market Participant Categorization
  • 8.3 Company Profiles
    • 8.3.1 Samsung BioLogics
      • 8.3.1.1 Company overview
      • 8.3.1.2 Financial performance
      • 8.3.1.3 Product benchmarking
      • 8.3.1.4 Strategic initiatives
    • 8.3.2 WuXi Biologics
      • 8.3.2.1 Company overview
      • 8.3.2.2 Financial performance
      • 8.3.2.3 Product benchmarking
      • 8.3.2.4 Strategic initiatives
    • 8.3.3 Celltrion Inc.
      • 8.3.3.1 Company overview
      • 8.3.3.2 Financial performance
      • 8.3.3.3 Product benchmarking
      • 8.3.3.4 Strategic initiatives
    • 8.3.4 PT Kalbe Farma Tbk
      • 8.3.4.1 Company overview
      • 8.3.4.2 Financial performance
      • 8.3.4.3 Product benchmarking
      • 8.3.4.4 Strategic initiatives
    • 8.3.5 Eurofins Advinus
      • 8.3.5.1 Company overview
      • 8.3.5.2 Financial performance
      • 8.3.5.3 Product benchmarking
      • 8.3.5.4 Strategic initiatives
    • 8.3.6 Covance Inc.
      • 8.3.6.1 Company overview
      • 8.3.6.2 Financial performance
      • 8.3.6.3 Product benchmarking
      • 8.3.6.4 Strategic initiatives
    • 8.3.7 Celerion
      • 8.3.7.1 Company overview
      • 8.3.7.2 Financial performance
      • 8.3.7.3 Product benchmarking
      • 8.3.7.4 Strategic initiatives
    • 8.3.8 Parexel International Corporation
      • 8.3.8.1 Company overview
      • 8.3.8.2 Financial performance
      • 8.3.8.3 Product benchmarking
      • 8.3.8.4 Strategic initiatives
    • 8.3.9 GVK Biosciences Private Limited
      • 8.3.9.1 Company overview
      • 8.3.9.2 Financial performance
      • 8.3.9.3 Product benchmarking
      • 8.3.9.4 Strategic initiatives
    • 8.3.10 Vifor Pharma Asia Pacific Pte. Ltd
      • 8.3.10.1 Company overview
      • 8.3.10.2 Financial performance
      • 8.3.10.3 Financial performance
      • 8.3.10.4 Product benchmarking
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.